Etanercept (Enbrel®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32013001029
English
Authors' recommendations:
Etanercept (Enbrel®) is recommended as an option for use within NHS Wales for the treatment of: •polyarthritis (rheumatoid factor positive or negative) in children aged 2 to < 4 years and extended oligoarthritis in children and adolescents ≥ 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate; •psoriatic arthritis in adolescents ≥ 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate; •enthesitis-related arthritis in adolescents ≥ 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/1437
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Arthritis
- Arthritis, Psoriatic
- Child
- Child, Preschool
- Adolescent
- Immunoglobulin G
- Receptors, Tumor Necrosis Factor
- Antirheumatic Agents
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.